source
- GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyoutIn a major stumble for GSK’s $2 billion acquisition of Bellus Health, the UK pharma said Friday it is ending development of camlipixant in refractory chronic cough (RCC) after the drug ...Endpoints · 13d ago↗ source
- Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire→ Silvia Luque announced on LinkedIn that she was named head of US marketing at Zealand Pharma after 13 years in various roles at obesity competitor Eli Lilly. She had been ...Endpoints · 13d ago↗ source
- Mirador unveils part of pipeline with drug from Kira to rival TavneosMirador Therapeutics, the secretive immune disease biotech with more than $650 million in VC funding, is finally revealing a piece of its pipeline. The San Diego biotech said Thursday it reached a…